Literature DB >> 3801283

Enhancement of cytotoxicity of vindesine and cis-platinum for human lung tumours by the use of verapamil in vitro.

A P Simmonds, P Moyes, A Nicol, K G Davidson, A Faichney.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3801283      PMCID： PMC2001606          DOI： 10.1038/bjc.1986.274

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  7 in total

1.  In vitro drug assay: pharmacologic considerations.

Authors:  D S Alberts; H S Chen; S E Salmon
Journal:  Prog Clin Biol Res       Date:  1980

2.  Reversal of adriamycin resistance by verapamil in human ovarian cancer.

Authors:  A M Rogan; T C Hamilton; R C Young; R W Klecker; R F Ozols
Journal:  Science       Date:  1984-06-01       Impact factor: 47.728

3.  Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: a randomized study.

Authors:  J A Elliott; S Ahmedzai; D Hole; A J Dorward; R D Stevenson; S B Kaye; S W Banham; B H Stack; K C Calman
Journal:  Eur J Cancer Clin Oncol       Date:  1984-08

4.  Promotion by verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug.

Authors:  T Tsuruo; H Iida; K Naganuma; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

5.  Potentiation of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1983-05       Impact factor: 12.701

6.  Drug sensitivity of non small cell carcinoma of lung by clonogenic assay in several media.

Authors:  A P Simmonds; P S Hamilton; H Kerr; K Harvey; P Moyes; K G Davidson; A Faichney
Journal:  Br J Cancer       Date:  1986-10       Impact factor: 7.640

7.  Resistance of human glioma to adriamycin in vitro: the role of membrane transport and its circumvention with verapamil.

Authors:  S Merry; C A Fetherston; S B Kaye; R I Freshney; J A Plumb
Journal:  Br J Cancer       Date:  1986-01       Impact factor: 7.640
  7 in total
  1 in total

1.  Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP16.

Authors:  M A Smith; S Merry; J G Smith; S B Kaye
Journal:  Br J Cancer       Date:  1988-06       Impact factor: 7.640
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.